Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections

Autor: Kiyoshi Suzuma, Yuko Miwa, Tomoaki Murakami, Koichiro Manabe, Yukari Takasago, Yuto Iida, Yuki Muraoka, Rie Osaka, Mamoru Kobayashi, Akitaka Tsujikawa, Sotaro Ooto
Rok vydání: 2017
Předmět:
Adult
Male
Vascular Endothelial Growth Factor A
Time Factors
Visual acuity
Fundus Oculi
VEGF receptors
Visual Acuity
Angiogenesis Inhibitors
Drug Administration Schedule
Macular Edema
03 medical and health sciences
0302 clinical medicine
Central retinal vein occlusion
Pro re nata
Ranibizumab
Retinal Vein Occlusion
medicine
Humans
Macula Lutea
Prospective Studies
Dosing
Fluorescein Angiography
Macular edema
Aged
Aged
80 and over
Dose-Response Relationship
Drug
biology
business.industry
General Medicine
Middle Aged
medicine.disease
Sensory Systems
Ophthalmology
Regimen
Anti–vascular endothelial growth factor therapy
Treatment Outcome
Anesthesia
Intravitreal Injections
030221 ophthalmology & optometry
biology.protein
Female
medicine.symptom
business
Tomography
Optical Coherence
030217 neurology & neurosurgery
Follow-Up Studies
Zdroj: Ophthalmologica. 239:27-35
ISSN: 1423-0267
0030-3755
Popis: Purpose: To compare the 12-month efficacy of 1 initial intravitreal injection of an anti-vascular endothelial growth factor (VEGF) agent followed by pro re nata (PRN) dosing with that of 3 initial monthly injections followed by PRN dosing in patients with macular edema (ME) after central retinal vein occlusion (CRVO). Methods: Twenty-nine eyes received 1 initial injection (1+PRN group) and 20 received 3 monthly injections (3+PRN group). Results: At month 12, changes in logMAR visual acuity from baseline were -0.172 ± 0.372 and -0.142 ± 0.317 in the 1+PRN and 3+PRN groups, respectively; the difference was not significant (p = 0.769). The number of anti-VEGF injections administered in the 3+PRN group (5.9 ± 2.1) was significantly greater than that in the 1+PRN group (4.1 ± 2.8; p = 0.022). Conclusion: When used for ME after CRVO, a 1+PRN regimen achieved 12-month outcomes similar to those of a 3+PRN regimen with fewer injections.
Databáze: OpenAIRE
Externí odkaz: